Arrowhead Pharmaceuticals Finalizes Global Licensing and Collaboration Deal with Novartis

Arrowhead Pharmaceuticals Announces Completion of Global Licensing and Collaboration Agreement with Novartis Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company focused on developing innovative RNA interference (RNAi) therapeutics, announced today that its previously disclosed global licensing and collaboration agreement…

Read MoreArrowhead Pharmaceuticals Finalizes Global Licensing and Collaboration Deal with Novartis

STARLIMS Unveils QM Essentials: Leading Cloud LIMS for SMB Batch Manufacturing

STARLIMS Introduces QM Essentials: A Cloud-Based LIMS Designed for SMB Batch Manufacturers a global leader in Laboratory Information Management Systems (LIMS) and informatics solutions, has announced the launch of Quality Manufacturing (QM) Essentials, a new cloud-based LIMS designed specifically for…

Read MoreSTARLIMS Unveils QM Essentials: Leading Cloud LIMS for SMB Batch Manufacturing

AskBio Publishes 12-Month Phase 1 AB-1002 Gene Therapy Data for Congestive Heart Failure in Nature Medicine

Long-Term Data Demonstrate Safety and Preliminary Efficacy of Investigational One-Time Gene Therapy in Patients with Non-Ischemic Heart Failure  AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the publication…

Read MoreAskBio Publishes 12-Month Phase 1 AB-1002 Gene Therapy Data for Congestive Heart Failure in Nature Medicine

Merck Publishes Long-Term Phase 3 Data on OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology

Merck Publishes Long-Term Phase 3 DeFi Trial Results Demonstrating Sustained Efficacy and Safety of OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology Merck, a leading science and technology company, announced the publication of long-term efficacy and safety findings…

Read MoreMerck Publishes Long-Term Phase 3 Data on OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology

Materion Corporation Schedules Third Quarter 2025 Financial Results Announcement for October 29

Materion Corporation to Announce Third Quarter 2025 Financial Results on October 29, 2025 Materion Corporation (NYSE: MTRN), a leading global provider of advanced materials solutions, has announced that it will release its financial results for the third quarter of 2025…

Read MoreMaterion Corporation Schedules Third Quarter 2025 Financial Results Announcement for October 29